Loading organizations...
Nextech Invest is a Zurich-based investment firm specializing in precision medicine, particularly identifying and fueling the success of emerging biotechnology companies focused on transformative cancer medicines. The firm actively nurtures its portfolio through critical stages of scientific validation and value creation, leveraging deep scientific insight combined with investment rigor to advance novel therapeutic solutions.
Dr. Alfred Scheidegger founded Nextech Venture AG, which later became Nextech Invest AG, in 1998. Prior to establishing Nextech, Dr. Scheidegger held significant roles, including managing director and board member at the Swiss Federal Institute. His vision for the firm stemmed from an insight into identifying promising biotechnologies to accelerate advancements in cancer treatment through strategic capital and guidance.
Nextech Invest serves emerging biotechnology companies developing innovative cancer therapies. The firm's long-term vision centers on accelerating the next generation of precision medicines, aiming to bring significant advancements in healthcare to patients worldwide. They are dedicated to finding and fueling tomorrow’s medical breakthroughs, striving to create lasting impact for patients.
Key people at Nextech Invest.
Nextech Invest is a Zurich-based venture capital firm specializing in oncology therapeutics within the biotechnology sector. Its mission centers on identifying and fueling transformative cancer medicines by investing in promising drug discovery companies primarily in the US and Europe. The firm focuses on precision medicine and supports portfolio companies through critical scientific and clinical validation stages to drive value creation. Nextech’s investment philosophy emphasizes deep scientific rigor and long-term partnership to build resilient companies capable of delivering multiple medicines for cancer treatment[1][2][3][6][7].
Founded in 1998, Nextech Invest was established to power the future of precision medicine, with a strong focus on oncology therapeutics. The firm’s evolution has maintained a consistent focus on early-stage and crossover investments in drug discovery companies, leveraging its scientific expertise and hands-on board leadership to support company development from inception through clinical proof-of-concept. Key partners and leadership combine deep scientific knowledge with investment experience, enabling Nextech to add significant strategic value beyond capital[2][4][6].
Nextech Invest rides the growing global trend toward precision medicine and targeted cancer therapies, a sector driven by advances in genomics, molecular biology, and drug delivery technologies. The timing is favorable due to increasing demand for more effective, personalized cancer treatments and the expanding biotech innovation ecosystem in both the US and Europe. By focusing on oncology drug discovery, Nextech influences the broader ecosystem by accelerating the translation of cutting-edge science into clinical-stage therapies, thereby contributing to improved patient outcomes and advancing the biotech industry’s maturity[3][6][7].
Looking ahead, Nextech Invest is poised to continue leveraging its deep oncology expertise and scientific validation capabilities to back next-generation cancer therapeutics. Trends such as RNA editing, antibody-drug conjugates, and AI-driven drug discovery will likely shape its portfolio evolution. As precision medicine becomes increasingly central to oncology treatment paradigms, Nextech’s influence may grow through further strategic partnerships and expanded investments across emerging modalities. Its sustained focus on value creation and resilience positions it well to remain a key player in the biotech venture capital landscape, fueling tomorrow’s advances in cancer care[6][7].
Nextech Invest has 6 tracked investments across 6 companies. The latest tracked deal is $130.0M Series B in Alterome Therapeutics in April 2024.
Key people at Nextech Invest.
